Glucocorticoid receptor activation leads to up-regulation of adenosine A1 receptors and down-regulation of adenosine A2 responses in DDT1 MF-2 smooth muscle cells.
The effect of glucocorticoid treatment of DDT1 MF-2 smooth muscle cells on the signaling via two adenosine receptors with opposing actions on cAMP generation was examined. Treatment with dexamethasone caused a dose- and time-dependent increase in the number of adenosine A1 receptors but did not affect the KD or the proportions of receptors in high and low affinity states. The EC50 was 1 nM dexamethasone, and maximal response was achieved after 24 hr. The number of receptors was increased by approximately 50%. Other steroid hormones, including aldosterone, progesterone, testosterone, and estrogen, were much less effective, and addition of the glucocorticoid receptor antagonist RU 486 or the protein synthesis inhibitor cycloheximide prevented the up-regulation, showing that the effect was mediated via a glucocorticoid receptor-specific mechanism that involves protein synthesis. In dexamethasone-treated cells the A1 receptor agonist (-)-N6-phenylisopropyladenosine [(R)-PIA] was 3 times more potent as an inhibitor of cAMP formation induced by isoprenaline than in untreated cells. ADP ribosylation of inhibitory GTP-binding proteins by pertussis toxin completely prevented (R)-PIA from inhibiting cAMP accumulation. A further analysis of the different GTP-binding proteins, including the three Gi subtypes (Gi1, Gi2, and Gi3), revealed no quantitative or qualitative change after dexamethasone treatment. In addition, the adenosine A2 receptors were down-regulated, as indicated by the fact that the ability of the A2 receptor agonist 5'-N-ethylcarboxamidoadenosine to increase cAMP formation was decreased by 20-30% in dexamethasone-treated cells. In summary, we have shown that A1 and A2 receptors on the same cell are differentially regulated by glucocorticoids and that this has functional importance in the regulation of cAMP accumulation.
Gerwins
P
P
Department of Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Fredholm
B B
BB
D000818:Animals; D006224:Cricetinae; D000242:Cyclic AMP / Q000378:metabolism; D003513:Cycloheximide / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D015536:Down-Regulation; D019204:GTP-Binding Proteins / Q000032:analysis / Q000502:physiology; D008647:Mesocricetus; D009130:Muscle, Smooth / Q000737:chemistry* / Q000187:drug effects; D010660:Phenylisopropyladenosine / Q000494:pharmacology; D011965:Receptors, Glucocorticoid / Q000502:physiology*; D011983:Receptors, Purinergic / Q000032:analysis* / Q000187:drug effects / Q000235:genetics; D015854:Up-Regulation; D014970:Xanthines / Q000378:metabolism
D011965:Receptors, Glucocorticoid; D011983:Receptors, Purinergic; D014970:Xanthines; D010660:Phenylisopropyladenosine; D003907:Dexamethasone; D003513:Cycloheximide; C051360:1,3-dipropyl-8-cyclopentylxanthine; D000242:Cyclic AMP; D019204:GTP-Binding Proteins